iShares Genomics Immunology and Healthcare ETF
IDNA
86 hedge funds and large institutions have $73.8M invested in iShares Genomics Immunology and Healthcare ETF in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 29 closing their positions.
0.98% less ownership
Funds ownership: 32.59% → 31.61% (-0.98%)
17% less funds holding
Funds holding: 103 → 86 (-17)
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
36% less capital invested
Capital invested by funds: $115M → $73.8M (-$41.6M)
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.64M |
| 2 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
+$3.05M |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$1.53M |
| 4 |
WAP
Wealthcare Advisory Partners
West Chester,
Pennsylvania
|
+$1.23M |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$737K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.26M |
| 2 |
RCS
Retirement Capital Strategies
San Jose,
California
|
-$3.5M |
| 3 |
Jane Street
New York
|
-$3.25M |
| 4 |
SHJ
Sharkey, Howes & Javer
Denver,
Colorado
|
-$2.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.36M |
IDNA Hedge Fund Activity: Q1 2022 in Review
86 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q1 2022, worth a combined $73.8M — down 36% from $115M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of IDNA and 15 opened new positions — a net loss of 14 holders — while 30 trimmed existing stakes and 22 added.
The largest buyer was Bank of America, adding an estimated $4.64M. The largest seller was UBS Group, cutting an estimated $4.26M.
- 86 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q1 2022, down from 103 in Q4 2021.
- Funds reported $73.8M of iShares Genomics Immunology and Healthcare ETF stock for Q1 2022, down 36% quarter-over-quarter.
- 15 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q1 2022 and 29 closed out, a net change of -14 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q1 2022 was Bank of America, an estimated $4.64M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q1 2022 was UBS Group, an estimated $4.26M sold.
Based on aggregated 13F filings for Q1 2022.